Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$74,676 | -$139,674 | -$256,256 | -$284,126 |
| Dep. & Amort. | -$8,521 | $528 | $656 | $533 |
| Deferred Tax | $0 | $0 | $0 | -$4,080 |
| Stock-Based Comp. | $64,035 | $52,832 | $43,013 | $34,303 |
| Change in WC | -$54,097 | -$29,577 | -$58,136 | -$6,353 |
| Other Non-Cash | $82 | -$8,308 | $537 | $179 |
| Operating Cash Flow | -$73,177 | -$124,199 | -$270,186 | -$259,543 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$322 | -$269 | -$778 | -$326 |
| Net Acquisitions | $0 | $0 | $127,595 | -$280,669 |
| Inv. Purchases | -$739,679 | -$415,269 | -$759,209 | -$224,575 |
| Inv. Sales/Matur. | $404,851 | $521,079 | $631,614 | $505,244 |
| Other Inv. Act. | $0 | $0 | -$127,595 | $280,669 |
| Investing Cash Flow | -$335,150 | $105,541 | -$128,373 | $280,344 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $543,086 | $17,810 | $433,718 | $11,519 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $24,422 | $17,810 | $21,441 | $11,519 |
| Financing Cash Flow | $567,508 | $17,810 | $455,159 | $11,519 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $159,181 | -$848 | $56,600 | $32,319 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $149,517 | $150,365 | $93,765 | $61,446 |
| End Cash | $308,698 | $149,517 | $150,365 | $93,765 |
| Free Cash Flow | -$73,499 | -$124,468 | -$270,964 | -$259,869 |